Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Cathomas
R
R
Department of Internal Medicine, Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland. Electronic address: richard.cathomas@ksgr.ch.
von Moos
R
R
Department of Internal Medicine, Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland.
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000187:drug effects / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007150:Immunohistochemistry; D000077341:Lapatinib; D008875:Middle Aged; D018396:Mucin-1 / Q000187:drug effects / Q000378:metabolism; D011799:Quinazolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D013921:Thrombocytopenia / Q000139:chemically induced*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D018396:Mucin-1; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab